Myovant, Pfizer’s expansion bid for Myfembree hits a snag at the FDA
Myovant and Pfizer’s endometriosis expansion bid for Myfembree has hit a pothole late in the FDA’s review process.
In a letter to the companies, the United States...
Continue Reading →
